What Sincrolab does

Sincrolab S.L. is a Spanish digital therapeutics company, founded in 2013 and headquartered in Madrid (with a registered office in Málaga), that develops AI-powered cognitive therapy software for ADHD and related cognitive disorders. Its core product, the KAD_SCL_01 cognitive stimulation program, deploys 14 adaptive cognitive tasks (including go/no-go and n-back paradigms) through the gamified 'Sea of Heroes' mobile application, with an AI engine that automatically adjusts task content and difficulty in real time based on each patient's daily performance. A separate professional platform allows therapists, clinics, and hospitals to prescribe treatment, monitor compliance, and generate automated progress reports, while families access the program through the Sincroclinic online booking and subscription flow.

Sincrolab holds CE Class IIa certification under EU Medical Device Regulation 2017/745 as the first Spanish company to secure this designation for an AI-based digital ADHD therapy, alongside ISO 13485:2016 (medical device quality) and ISO/IEC 27001:2022 (information security) certifications. Clinical validation rests on three peer-reviewed randomized controlled trials published in the Journal of Medical Internet Research (2021), Brain Communications (2022), and npj Mental Health Research/Nature (2025), with the most recent study reporting 28% of treated children reaching normative range on CPT-C versus 0% in controls and MEG-verified changes in brain activity.

The company monetizes through a €99/month B2C subscription sold directly to families via sincrolab.es, complemented by B2B subscriptions for healthcare professionals and partnerships with clinics, hospitals, and insurers (notably DKV), reaching a reported network of 800+ therapists and 100+ specialized centers across Spain with 6,000+ patients treated to date. Sincrolab has raised approximately €2 million cumulatively across rounds including Wayra (2015, 2018), a €1.7 million round led by Clave Innohealth in June 2024, and a 2026 Eoniq.fund follow-on at an €8.5 million pre-money valuation, with stated priorities of international expansion and new product launches in 2025.

Name

Sincrolab

Legal name

SINCROLAB S.L.

Website

https://sincrolab.es

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Sincrolab is a Spanish digital therapeutics company that delivers CE-marked, AI-adaptive cognitive therapy for ADHD through its gamified 'Sea of Heroes' platform, sold via €99/month subscriptions to families and through professional licenses to clinicians, clinics, and hospitals across Spain.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for ADHD

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Prepackaged Software (7372), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching) (HLALAEAJ), Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)

Keywords

• Digital cognitive therapy
• ADHD treatment platform
• AI cognitive stimulation
• Pediatric mental health
• Gamified neurotherapy

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Suscripción Mensual Sincrolab (B2C): Monthly subscription model at €99/month for families, automatically renewed. Includes initial clinical assessment, personalized treatment plan, daily cognitive training activities via Sea of Heroes app, and ongoing professional supervision throughout the treatment cycle.
2. B2B Platform Licensing / Professional Subscriptions: Sincrolab provides its professional platform to therapists, clinics, and hospitals who prescribe and monitor patient treatment. The platform allows professionals to customize treatment plans, supervise progress remotely, and generate automated reports for their patient base.
3. Partnerships with Medical and Pharmaceutical Entities: Sincrolab is pursuing partnerships with medical and pharmaceutical entities as part of its expansion strategy, as stated in the Eoniq.fund investment announcement.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Sincrolab provides an AI-powered digital therapeutic platform for cognitive stimulation in children (and adults) with ADHD and attention difficulties. Its flagship product, the KAD_SCL_01 program, is delivered through the gamified 'Sea of Heroes' mobile app and comprises 14 adaptive cognitive tasks (go/no-go, n-back, etc.) that auto-adjust to patient performance, with online clinical assessment, monthly subscription pricing (€99/month), and ongoing professional supervision. A separate professional platform allows therapists, clinics, and hospitals to prescribe, monitor, and report on patient progress remotely.

Product overview

Sincrolab is a digital therapeutics company offering a unified platform combining AI-powered cognitive therapy (KAD_SCL_01) for ADHD and cognitive disorders. The core offering consists of the Sincrolab Platform for patients and professionals, the Sea of Heroes gamified therapy experience, and the Sincroclinic scheduling service. The platform is validated by clinical trials published in peer-reviewed journals including JMIR, Brain Communications, and Nature npj Mental Health Research, and holds CE Class IIa certification as a medical device for ADHD treatment. Pricing is via €99/month subscription through Sincroclinic.

Differentiator

Problem solved

Functional benefit

Brands

• Sea of Heroes: A digital experience designed to accompany daily life with personalized activities, more motivation, and professional follow-up. A serious game with 14 cognitive tasks including go/no-go and n-back exercises that automatically adjust content and difficulty based on performance.

Products and services

• Sincrolab Platform
• Sea of Heroes
• Sincrolab Therapist Platform
• Sincroclinic
• KAD_SCL_01 Cognitive Stimulation Program

Quantifiable outcome

• 28% of the experimental group reached normative range on CPT-C (7/25 participants) vs 0% in control group (p=0.009), as demonstrated in the Nature npj Mental Health Research 2025 RCT
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Six partnerships are on record, tiered minor and core.

• DKVminorGTM or Marketing PartnerDKV, a health insurance company, has a partnership or collaboration with Sincrolab. The DKV logo appears in the collaborators section on Sincrolab's professional platform page alongside Wayra, CTB, ELMA, Laboratorios Rubio, and IBM.
• WayraminorGTM or Marketing PartnerWayra (Telefónica's tech venture capital / accelerator arm) appears in the collaborators section of Sincrolab's professional platform. The connection likely relates to Sincrolab's prior acceleration by Telefónica.
• CTB (Centro de Tecnología Biomédica, UPM)coreStrategic or Co-development PartnerCTB (Centro de Tecnología Biomédica of Universidad Politécnica de Madrid) appears in the collaborators section. Fernando Maestú PhD, Director of the Cognitive Neuroscience and Computacional Lab at CTB, UPM, and UCM, serves on Sincrolab's Scientific Advisory Board, indicating a research collaboration.
• ELMAminorGTM or Marketing PartnerELMA appears in the collaborators section on Sincrolab's professional platform page. No further details available on the nature of the collaboration.
• Laboratorios RubiominorStrategic or Co-development PartnerLaboratorios Rubio appears in the collaborators section. Sincrolab has announced intentions to develop partnerships with medical and pharmaceutical entities, which may include Laboratorios Rubio.
• TelefónicaminorGTM or Marketing PartnerSincrolab was accelerated by Telefónica, a major Spanish telecommunications and technology corporation. This affiliation provides potential go-to-market support, network access, and brand credibility within the Spanish tech ecosystem.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• BehaVR: Developer of VR-based digital therapeutics for mental health and chronic pain conditions. Comparable as an emerging immersive-therapy DTx peer pursuing evidence-based, clinician-prescribed digital interventions, though using VR rather than mobile cognitive training.
• Woebot Health: AI-driven conversational mental health platform delivering CBT-informed chatbot interventions. Comparable in using AI to scale evidence-based mental health support and targeting the same clinician-payer ecosystem, though focused on conversational AI rather than adaptive cognitive training.
• Mahana Therapeutics: Developer of prescription digital therapeutics including treatments for IBS (Mahana IBS) and tinnitus. Comparable as an emerging DTx peer pursuing regulatory-cleared, evidence-based software therapies in adjacent chronic-condition categories.
• Limbic: AI-powered mental health platform supporting NHS psychological therapy services in the UK through patient-facing AI and clinician decision-support tools. Comparable in using AI to personalize mental-health interventions and reduce clinician burden, though operating in IAPT pathways rather than ADHD specifically.

Broad incumbents

• Cerebral: Broad digital mental health platform offering online ADHD evaluation, medication management, and therapy subscriptions in the U.S. Comparable as a scaled ADHD-focused digital mental health player, though operating with a telemedicine + prescribing model rather than a software-as-medical-device approach.
• Big Health: Digital therapeutics company behind Sleepio (insomnia) and Daylight (anxiety), delivering FDA-cleared and evidence-based cognitive behavioral therapies via mobile. Comparable as an established DTx competitor in mental health, though focused on sleep/anxiety rather than ADHD.

Direct peers

• Akili Interactive: Maker of EndeavorRx, the first FDA-cleared prescription video game-based digital therapeutic for pediatric ADHD. Directly comparable to Sincrolab in target indication (pediatric ADHD), delivery (mobile gamified cognitive therapy), regulatory pathway (cleared medical device), and GTM (clinician-prescribed, payor-reimbursed).
• Posit Science: Developer of BrainHQ, a clinically validated cognitive training platform targeting attention, memory, and brain performance. Comparable in deploying gamified adaptive cognitive exercises with peer-reviewed efficacy data, though targeting a broader consumer and clinical audience than Sincrolab's ADHD-specific focus.
• Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across mental health indications (depression, schizophrenia, migraine). Comparable as a DTx peer pursuing FDA-cleared, clinician-prescribed digital therapies in adjacent neuropsychiatric indications.
• Cogstate: Provider of computerized cognitive assessment and training tools used in clinical trials and clinical practice. Comparable through its combination of validated cognitive testing (CPT-style measures) and clinician-facing cognitive health technology, overlapping with Sincrolab's evidence-based positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/sincrolab_es
• YouTubeyoutube.com/channel/sincrolab
• Facebookfacebook.com/599090833509251
• LinkedInlinkedin.com/company/5088877
• Instagraminstagram.com/sincrolab
• TikToktiktok.com/@sincrolab

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sincrolab